Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 2 versus THYROLAR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 2 versus THYROLAR 5.
THYROLAR-2 vs THYROLAR-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyrolar-2 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing metabolic rate, oxygen consumption, and protein synthesis.
Thyrolar-5 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to T3 in peripheral tissues. T3 binds to thyroid hormone receptors, regulating gene transcription and increasing cellular metabolism.
1/2 to 1 tablet (30-60 mg liotrix) orally once daily, titrated every 2-4 weeks by 1/2 tablet increments based on clinical response and thyroid function tests.
Oral, starting dose 15-30 mg daily, titrated to maintenance dose of 60-120 mg daily, divided into 2-3 doses.
None Documented
None Documented
6-7 days (euthyroid); clinical context: steady-state reached in 4-6 weeks
Liothyronine (T3): 1-2 days; Levothyroxine (T4): 6-7 days. Clinical context: In hyperthyroidism, T4 half-life shortens to 3-4 days; in hypothyroidism, prolongs to 9-10 days
Renal: 40% (as glucuronide and sulfate conjugates); Fecal: 20% (unabsorbed); Biliary: minor (<5%)
Renal: 40-50% (as conjugated metabolites); Fecal: 20-30% (enterohepatic recirculation); Biliary: minor
Category C
Category C
Thyroid Hormone
Thyroid Hormone